BioSpace News Archive

Albany NY, United States: The increasing number of bone density disorders especially among the geriatric population is projected to aid in the expansion of the bone densitometers market.

Albany NY, United States: The global veterinary hematology analyzers displays a highly competitive market landscape with a few prominent players holding more than 50 percent of the market’s share, reports Transparency Market Research.

Calliditas Therapeutics AB announced that the company has expanded its licensing agreement with Everest Medicines II Limited to extend the territory covered to include South Korea.

SIFI S.p.A., a leading international ophthalmic pharmaceutical company, announced that the U.S. Food and Drug Administration has approved the company’s Orphan Drug Designation application for its investigational anti-infective polymer polihexanide for the treatment of fungal keratitis.

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres® (ephedrine hydrochloride) injection.

AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company, reported financial results for the fourth quarter and full year ended December 31, 2021, and provided financial guidance for 2022.

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it has been selected to give an oral presentation on exploring the immune-tumor microenvironment using high resolution single-cell spatial transcriptomics at the Keystone Symposium on Cancer Immunotherapy to take place on March 20-24, 2022.

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the entry into a definitive agreement to acquire FGen AG (“FGen”), a Swiss company specializing in strain development and optimization.

Catamaran Bio, Inc., today announced an expansion and extension of its research collaboration with Branden Moriarity, PhD, of the University of Minnesota, to further advance the versatility of transposon engineering for arming CAR-NK cell therapies with functional attributes not found in earlier generations of cell therapies.

Lineage Cell Therapeutics, Inc. today announced that full results from a Phase 1/2a clinical study of RG6501 will be presented at the 2022 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2022), to be held May 1 – 4, 2022 at the Colorado Convention Center in Denver, CO.